Olivier Taelman is an experienced MedTech leader, joining Nyxoah in July 2019 as Chief Operating and Commercial Officer and subsequently being appointed as CEO in November 2019.  Olivier spent 7 years in commercial healthcare at Eli Lilly and Sanofi Aventis leading specific Business Units. He spent 15 years within the field of neuromodulation at Medtronic, managing EMEA at Stryker NeuroVascular and serving a neuromodulation company Nevro where he was responsible for building the European business during the successful NASDAQ IPO.

Fabian Suarez Gonzalez is the Company's CFO. He joined Nyxoah in 2014 to take the leadership of the finance department. He is an experienced executive, having held senior roles in several private equity firms between 2005 and 2014. For five years he was CFO of TTR Energy, an investment vehicle which co-managed several private equity funds for which he supervised due diligence processes related to acquisitions and asset sales. Prior to this, he served as consultant for major financial conglomerates in matters related to risk and asset management.

Bruno Onkelinx has 25 years of experience in highly regulated industries with the last 15 years in active implantable medical devices at Cochlear. At Cochlear he built successful teams while managing international research & development and manufacturing operations across Europe-Belgium and the US-Colorado. He led several core Cochlear products from ideation through development to commercial approval and manufacturing. During his last years at Cochlear, Bruno was leading global incubation activities supporting business development activities and external medical device start/scale-ups.

An Moonen joined Nyxoah in December 2020 as General Counsel, bringing over 20 years of experience. After 11 years at Linklaters (Corporate M&A), she joined cell therapy company TiGenix in 2011 where she oversaw all legal and compliance matters as General Counsel and Company Secretary. An was involved in various strategic licensing, financing and M&A transactions, including TiGenix’ Nasdaq IPO and its takeover by Takeda. An holds a law degree from the KU Leuven and a Master of Laws (LLM) degree from New York University School of Law. She is a member of the New York Bar.

Jeremy Feffer brings to Nyxoah 20 years of experience in healthcare capital markets as a sell-side equity research analyst and an investor relations advisor. Jeremy covered medical device, diagnostics, and healthcare services companies as an analyst at Bank of America, Oppenheimer, and Cantor Fitzgerald. As an IR Director at LifeSci Advisors, he developed and executed comprehensive capital markets, corporate access, and messaging strategies for pre-IPO and publicly-traded healthcare companies. Jeremy holds an MBA from the Stern School of Business at New York University, a Diploma in Economics from the London School of Economics.

Nathalie Gilat has over 14 years of experience in global clinical & regulatory affairs. When joining Nyxoah in 2014, Nathalie played a key role in its initial clinical studies obtaining CE mark and regulatory milestones in the US. Currently, Nathalie is leading the Israeli organization as General Manager. Prior to Nyxoah, Nathalie held various managerial roles in innovative medical device companies, such as Valtech Cardio (acquired by Edwards Lifesciences) and Ovalum vascular. Nathalie holds a Biomedical Engineering degree from Ben-Gurion University and an MBA from Tel Aviv University.

Jeyakumar Subbaroyan has 14 years of experience in clinical and pre-clinical neuromodulation research in the fields of urology, migraine, spinal cord injury, and various chronic pain conditions. He has successfully executed multiple clinical studies across the US, Europe and Australia managing diverse global teams. He has 4 issued patents and over 20 peer-reviewed publications. Prior to Nyxoah, Jey held various positions of increasing responsibility in medical device companies including Johnson & Johnson, Spinal Modulation Inc. (acquired by St. Jude Medical), Nevro Corp. and Onward Medical Inc. to name a few.

Dorit has 13 years of experience in process manufacturing and quality management in highly regulated industries. She has successfully led both small and large groups in numerous manufacturing aspects including routine production, implementation of process changes, qualifications of new manufacturing sites and preparation to regulatory audits. She has extensive experience working in GMP and QSR/ISO 13485 regulated environments, including successful FDA, and EMA audits.

Dorit holds a MSc. in Food Engineering and Biotechnology from the Technion, Israel, a PhD in Integrative Biology from University of Texas Southwestern (UTSW) Medical Center Dallas, Texas, and an MBA from College of Management, Israel.

Rémi Renard has 15 years of experience in Sales and Marketing.  Throughout his career he has held multiple sales and marketing positions in medical device firms, mostly in the Cardiac Rhythm Management and OSA fields at Resmed, Boston Scientific and St. Jude Medical. Notably he successfully led sales and marketing activities related to the introduction in international markets of the first to market leadless pacemaker.

Patrick Tompkins has over 20 years of executive leadership experience in the medical device space. He joined Nyxoah in 2020 as VP of US Operations with responsibility for managing Nyxoah’s US operations in their IDE trial. Patrick has previous commercial leadership experience, both with global and domestic responsibilities in the cardiac and neuro fields. The last 13 years with neuromodulation companies, 8 of which were with St Jude Medical. Patrick has introduced and led the commercialization efforts, of first to market innovative technologies in both the cardiac and the neuromodulation spaces.